Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7437968 | 0.89 | SMN1; SMN2 (0.47) | CPB2BACE1APPNOS1NOS2 | |
| SCHEMBL26547322 | 0.88 | MAPT (0.47) | CPB2 | |
| SCHEMBL6783633 | 0.86 | KEAP1 (0.52) | KEAP1FFAR1CHRM1 | |
| SCHEMBL20366142 | 0.81 | KEAP1 (0.44) | KEAP1FFAR1CHRM1PLA2G10PLA2G2A | |
| SCHEMBL7797441 | 0.81 | ALDH1A1 (0.50) | BACE1NOS2ITGB3ITGAVITGA2B | |
| SCHEMBL2731062 | 0.81 | GABRA5 (0.47) | CPB2BACE1APP | |
| SCHEMBL29781523 | 0.81 | GABRA5 (0.47) | CPB2BACE1APP | |
| SCHEMBL18989631 | 0.80 | KDM4E (0.46) | BACE1NOS1NOS2 | |
| Hydrochloric Acid SCHEMBL5471608 | 0.79 | GABRA5 (0.46) | CPB2BACE1APP | |
| SCHEMBL5174055 | 0.79 | NOS1 (0.44) | CPB2BACE1APPNOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5255253-A | — | — | None | — | — | JP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6028087-A | Platelet aggregation inhibiting compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5548077-A | REACTING WITH CARBOHYDRATE COMPOUND TO FORM SCHIFF BASE, REDUCING SCHIFF BASE | SEIKAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1996-08-20 | — | — | US | disclosed |
| EP-0677043-A4 | — | — | 1995-11-22 | — | — | EP | disclosed |
| EP-0677043-A1 | PLATELET AGGREGATION INHIBITING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-18 | — | — | EP | disclosed |
| US-5386033-A | 2-aminopyridine compounds | SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) | 1995-01-31 | — | — | US | disclosed |
| WO-1994014775-A1 | PLATELET AGGREGATION INHIBITING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
| JP-H05255253-A | 2-AMINOPYRIDINE DERIVATIVE, PRODUCTION THEREOF AND FLUORESCENT MARKING AGENT | SEIKAGAKU KOGYO CO LTD | 1993-10-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | KEAP1 3496/4885CPB2 1139/4885BACE1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.